No Data
No Data
Fulcrum Therapeutics (NASDAQ:FULC) Shareholders Have Endured a 77% Loss From Investing in the Stock Three Years Ago
Subdued Growth No Barrier To Fulcrum Therapeutics, Inc. (NASDAQ:FULC) With Shares Advancing 32%
Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why
Fulcrum Therapeutics to Participate in Upcoming December Conferences
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)
Fulcrum Therapeutics Slides As Insider Purchases Lose Another US$362k
Unlock the Full List